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ess: rdales@ohri.ca (R.Summary Spirometry has been reported to be under-utilized, and airflow
obstruction may be under-diagnosed, in primary care practice.
Study objectives: The objective of this study was to determine the prevalence and
severity of airflow obstruction in rural primary care settings and the degree to which
it can be predicted by clinical characteristics. Spirometry was performed in patients
35 years and older who had smoked, presenting for any reason to one of eight rural
primary care practices. Obstruction was defined as an FEV1/FVCo0.70. A total of
1046 subjects were recruited of whom 1034 had acceptable and reproducible
spirometry. Airflow obstruction was detected in 17.4% (180 patients). Of those with
obstruction, 77.2% (SE 3.1%) had at least one respiratory symptom versus 62.4%
(SE 1.6%) without obstruction (P ¼ 0:0002). Only 44.9% (SE 3.7%) of those with airflow
obstruction had been previously diagnosed with obstructive lung disease. Of those
with an FEV1o50% of predicted, 85% (SE 5.6%) were breathless on exertion; however,
only 63% (SE 7.6%) were being treated with respiratory medications. We conclude
that airflow obstruction is common in rural primary care practice and cannot be
accurately predicted by symptoms. It is undiagnosed half of the time, and often not
treated even when symptomatic.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
Respirology, The Ottawa
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E. Dales).Introduction
Mild-to-moderate airflow obstruction, defined by
spirometry, is present in approximately 25% of adult
smokers.1 Evidence suggests that it is under-
diagnosed.2–4 One reason for under diagnosis is
that spirometry, the gold standard diagnostic tool,
is underutilized in clinical practice.5 Unfortunately,ed.
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Airflow obstruction in rural primary care 755the presence or absence of clinical findings is not
accurate to detect airflow obstruction.4 Increased
use of spirometry in the clinical setting has been
repeatedly recommended over the years6,7 with
perhaps the strongest statement coming from the
National Lung Health Education Program in the US
recommending: ‘the widespread use of office
spirometry by primary-care providers for patients
45 years or older who smoke cigarettes’.5
Surprisingly, despite the calls for screening
spirometry in the primary care setting, there exist
few studies about how much additional clinical
information spirometry imparts in this situation.8,9
To address this, we identified eight rural primary
care practices that previously had not had con-
venient access to spirometry. Spirometry was
carried out in these practices on patients who were
at least 35 years of age, had ever smoked, and who
presented for any reason to their primary care
physicians.
The objective of this study was to determine the
prevalence and severity of airflow obstruction in
rural primary care settings and the degree to which
it can be predicted by clinical characteristics. We
describe the prevalence of detected airflow ob-
struction by severity, by symptoms, by previous
clinical diagnosis, and by prior treatment.Methods
Geographic location: Primary care practices were
recruited from rural Eastern Ontario, Canada. They
had to be within a 2-h driving distance of The
Ottawa Hospital, which allowed the hospital-based
research assistants to drive to the practices each
day to perform spirometry. The practices could not
have spirometry on-site, or within the community,
in order to avoid contamination of results of clinical
diagnosis. Several rural communities were selected
to assess variability between practices. The prac-
tices were sent letters of invitation and then
telephoned. The first eight that agreed were
included in the study.
Subjects: Eligible subjects were all patients
presenting to their primary care practitioners for
any reason, who were at least 35 years of age, and
who had smoked at least 20 packages of cigarettes
in their lifetime. The patients were given a brief
questionnaire by the clinic receptionist that deter-
mined their age, smoking history, and asked
whether they would agree to participate. Those
patients who were eligible, and agreed to partici-
pate, were approached by the research assistant
and signed informed consent. Patients who couldnot perform spirometry were excluded. The study
was approved by The Ottawa Hospital Human Ethics
Committee.
Baseline data collection: Interviewer-adminis-
tered questionnaires included questions about
smoking, respiratory symptoms, and diagnosed
respiratory illnesses taken from the American
Thoracic Society (ATS) Questionnaire10 which has
been standardized and tested for reliability.
Spirometry was performed in the practice build-
ing by trained research assistants using a Microlab
3500s. Tests were performed according to the
American Thoracic Society criteria. Testing was
done with the subjects seated and a maximum
forced exhalation was carried out for a minimum of
6 s. A minimum of three and a maximum of eight
forced vital capacity (FVC) maneuvers were per-
formed to obtain at least three acceptable loops,
two of which were reproducible within 200ml. The
reference values used were those of Knudson et
al.11 All spirometry tests were reviewed by an
independent senior cardiopulmonary technologist
and two respirologists to ensure acceptability. If
the FEV1 was less than 80% or if the FEV1/FVC was
o0.7, then spirometry was repeated 20min after
two inhalations of salbutamol (Ventolins) from a
metered dose inhaler administered via a spacer
(Aerochambers).Statistical analysis
The criterion for prevalence of airflow obstruction
was a pre-bronchodilator FEV1/FVC less than 0.7.
Results were also stratified by severity based on the
FEV1. The w
2 statistic was used to test associations
between prevalence and risk factors: age, gender,
smoking, and respiratory symptoms. To determine
the prevalence of new diagnoses of airflow ob-
struction the presence of obstruction was stratified
by the presence or absence of reported physician-
diagnosed asthma, COPD, emphysema or chronic
bronchitis. Homogeneity of variance between
practices was tested prior to pooling the results.Results
The population of the eight communities ranged
between 1206 and 4406. Each practice was com-
posed of 1–7 participating physicians. A total of
1046 subjects were recruited into the study,
of whom 1034 had acceptable and reproducible
spirometry. One hundred and eighty patients
(17.4%) had airflow obstruction, defined as a
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Table 1 Characteristics of study population stratified by of the presence or absence of obstruction.
Characteristics Total cohort FEV1/FVC o70%
n ¼ 180
FEV1/FVC X70%
n ¼ 854
P-value for
group
differences
Age—mean (SD) 59.1 (12.7) 66.1 (12.3) 57.7 (12.3) 0.0001
Female n (%) 482 (46.6) 58 (32.2) 424 (49.7) o0.0001
Post-secondary education n (%) 250 (24.5) 39 (22.0) 211 (25.1) 0.3951
Smoking history—mean (SD)
Years of smoking 29.6 (14.1) 38.2 (14.5) 27.8 (13.4) o0.0001
Pack years of smoking 35.5 (28.5) 48.3 (29.2) 32.8 (27.6) o0.0001
Symptoms n (%)
Shortness of breath 482 (46.7) 106 (59.2) 376 (44.0) 0.0002
Cough 227 (22.0) 61 (33.9) 166 (19.5) o0.0001
Phlegm 221 (21.4) 56 (31.1) 165 (19.3) 0.0005
Wheeze 425 (41.1) 102 (56.7) 323 (37.8) o0.0001
Any of the symptoms 672 (65.0) 139 (77.2) 533 (62.4) 0.0002
Disease n (%)
Asthma 152 (14.8) 45 (25.3) 107 (12.6) o0.0001
COPD 35 (3.4) 19 (10.7) 16 (1.9) o0.0001
Emphysema 32 (3.1) 22 (12.4) 10 (1.2) o0.0001
Chronic bronchitis 150 (14.8) 35 (20.0) 115 (13.7) 0.0319
Any of the diseases 271 (26.5) 79 (44.9) 192 (22.7) o0.0001
Medication n (%) 195 (18.9) 68 (37.8) 127 (14.9) o0.0001
R.E. Dales et al.756pre-bronchodilator FEV1/FVCo0.70 (Table 1).
There was no significant difference in prevalence
of airflow obstruction between the 8 sites (w2
P ¼ 0:17). The mean age of the study patients was
59 year (95% CI, 58–60) with patient’s having a
mean 30 year history of smoking (95% CI, 27–29).
Nineteen percent of patients in the study (95% CI,
17–21) were taking respiratory medications (de-
fined as use of inhaled bronchodilators, inhaled
corticosteroids, or theophyline compounds). Physi-
cian-diagnosed obstructive respiratory diseases
such as asthma, COPD, emphysema, and/or chronic
bronchitis were reported in 26.5% (95% CI, 23–30%)
of the total cohort respectively (Table 1).
To determine the degree to which the study
group was representative of all eligible subjects,
the entire clinical population that visited the eight
primary care practices was surveyed for several
days. Of these 1800 subjects who were 100%
sampled, 561 were at least 35 years of age and
had ever smoked. Compared to all of those eligible
(age at least 35 year and had ever smoked), the
group studied with spirometry differed as follows:
2 years younger in age, 1% more males, and 1 year
more smoking.
Compared to those without obstruction, the
obstructed group was 8 years older with 9 moreyears of smoking (P ¼ 0:0001 for each difference)
(Table 1). Obstruction was present in 30% of those
over 65 years of age and in 10% of patients younger
than 40. Of those with airflow obstruction, 77.2% (SE
3.1%) had at least one respiratory symptom
(dyspnea, chronic cough, chronic sputum produc-
tion, or wheeze) versus 62.4% (SE 1.6%) of those
without airflow obstruction (P ¼ 0:0002). 44.9% (SE
3.7%) of those obstructed reported a physician-
diagnosis of asthma, COPD, emphysema, or chronic
bronchitis versus 22.7% (SE 1.2%) of those without
obstruction (P ¼ 0:0001). Use of a respiratory
medication was twice as common in those
with obstruction versus those without obstruction
(Table 1).
The obstructed group was stratified by severity
based on the % predicted FEV1 and patient
characteristics were tested for trend across the
subgroups (Table 2). Although men were more likely
to be obstructed than women (Table 1), gender was
not associated with increasing disease severity
(Table 2). Of the respiratory symptoms, breath-
lessness was significantly associated with increasing
severity of airflow obstruction (P ¼ 0:0001 for
trend), as was cough (P ¼ 0:04). The presence of
phlegm or wheeze was not significantly associated
with increasing severity of airflow obstruction.
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Table 2 Characteristics of subjects with an FEV1/FVCo70% stratified by severity of obstruction.
Characteristics FEV1X80
n ¼ 35
804FEV1X50
n ¼ 105
FEV1o50
n ¼ 40
P-value for trend
Age—mean (SD) 64.7 (12.9) 65.2 (12.5) 69.8 (10.3) 0.0740
Female n (%) 10 (28.6) 37 (35.2) 11 (27.5) 0.8799
Post-secondary education n (%) 9 (26.5) 22 (21.4) 8 (20.0) 0.5143
Smoking history—mean (SD)
Years of smoking 34.6 (14.4) 37.3 (15.3) 43.9 (10.6) 0.0057
Pack-years of smoking 43.9 (25.8) 46.7 (31.3) 56.5 (25.1) 0.0646
Symptoms n (%)
Shortness of breath 14 (40.0) 58 (55.8) 34 (85.0) o0.0001
Cough 10 (28.6) 31 (29.5) 20 (50.0) 0.0426
Phlegm 9 (25.7) 30 (28.6) 17 (42.5) 0.1076
Wheeze 17 (48.6) 59 (56.2) 26 (65.0) 0.1504
Any of the symptoms 23 (65.7) 79 (75.2) 37 (92.5) 0.0052
Disease n (%)
Asthma 6 (17.1) 28 (26.9) 11 (28.2) 0.2857
COPD 0 10 (9.6) 9 (23.1) 0.0012
Emphysema 1 (2.9) 10 (9.6) 11 (29.0) 0.0006
Chronic bronchitis 3 (8.6) 20 (19.6) 12 (31.6) 0.0139
Any of the diseases 9 (25.7) 43 (42.2) 27 (69.2) 0.0002
Medication n (%) 6 (17.1) 37 (35.2) 25 (62.5) o0.0001
Table 3 Prevalence of airflow obstruction, an FEV1/FVCo70% by quartiles of pack-years smoking history.
Pack-years of smoking (quartiles)
o15.5 (n ¼ 254) 15.5 to o31.0 (n ¼ 250) 31.0 to o48 (n ¼ 261) X48 (n ¼ 259)
FEV1/FVC o0.7 n ¼ 20, 7.8% n ¼ 24, 9.6% n ¼ 55, 21.1% n ¼ 80, 30.9%
Airflow obstruction in rural primary care 757Increased severity of obstruction was associated
with a previous history of physician-diagnosed
COPD (P ¼ 0:0012) and emphysema (Po0:001),
but not asthma.
Respiratory medications were more likely to
be prescribed in more severe cases of airflow
obstruction. However, only 62.5% of those
patients with an FEV1 o50% were being prescribed
respiratory medications despite the observa-
tion that 85% had at least grade-2 dyspnea based
on the Medical Research Council dyspnea scale
(breathless hurrying on the level or walking up a
slight hill).
Cumulative smoking history was expressed in
pack-years, the number of years smoked multiplied
by the number of cigarettes daily divided by 20.
Categorized into quartiles, there was a fourfold
increase in prevalence of obstruction, 7.9% v.
30.1%, from the lowest quartile (o15.5 pack-years)
to the highest (X48.0 pack-years), Po0:0001
(Table 3).Those who were not obstructed were not given a
bronchodilator. Of those who were obstructed and
administered a bronchodilator,163 remained ob-
structed. The number who had a FEV/FVC40.7
prebronchodilator was 854 which increased to 884
postbronchodilator. The prevalence of airflow ob-
struction was 17.4% prebronchodilator and 13.1%
postbronchodilator. Thirty-eight percent of those
whose FEV1/FVC ratio was o0.70 pre-bronchodi-
lator were taking respiratory medications versus
44% of those whose FEV1/FVC ratio remained
o0.70 post-bronchodilator. Respective values for
the percentage with any respiratory symptoms
were 77% and 82%.Discussion
Spirometry has often been recommended in pri-
mary care but apart from a study in China by
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R.E. Dales et al.758Takahashi et al. it has never been examined in this
setting. This study provided a unique insight into
the prevalence of obstruction in rural practices,
which are known to be under-serviced by spirome-
try when compared to larger cities.12 The results of
this study suggest that airflow obstruction is
common in rural primary care practice and cannot
be accurately predicted by symptoms. It is un-
diagnosed half of the time, and is often not treated
even when symptomatic. Apart from a history of a
previous diagnosis and management, pack-years
smoking was the strongest predictor, with a four-
fold increase between the lowest and highest
quartiles, i.e. o16 and X48 pack-years years.
A 100% sampling of the practices indicated that
the study group was representative of these
primary care practice populations. The 100%
sampling also indicated that 1/3 of the entire
clinic population was eligible for the study based on
age at least 35 years and having ever smoked.
A potential limitation of this study is that a very
simple definition of obstruction was selected,
FEV1/FVC o70%. This would bias the results in
the older population towards being obstructed
since the FEV1/FVC ratio falls with age. However,
one ratio applied to all ages is what is recom-
mended by the ATS and GOLD guidelines to
diagnose obstructive lung disease and this ratio
serves as a simple rule-of-thumb convenient for the
primary care setting.
Similar studies of the prevalence of airflow
obstruction in rural primary care practices could
not be found, but there have been previous
population- based and volunteer studies. Buist et
al.1 screened 73,694 cigarette smokers, aged 35–60
years, for participation in the Chronic Obstructive
Lung Disease Early Intervention Trial (Lung Health
Study). The sample was very large but not a
representative sample, since subjects were re-
cruited through the media, mail-outs and screening
in public places and work-sites. Smoking was
defined as having smoked at least 10 cigarettes in
1 day during the last 30 days. Twenty-five percent
of the subjects were found to have mild-to-
moderate airflow obstruction defined as an FEV1/
FVC ratio of o70% and an FEV1 between 55% and
90% of predicted using the reference values of
Crapo et al.13 Renwick and Connolly4 mailed a
questionnaire to 893 subjects at least 45 years of
age who were registered with 22 local general
practices in Central Manchester. Characteristics of
the 723 respondents were: mean age of 66 years,
57% women, 29% current smokers, and 37% ex-
smokers. Of the 240 patients who underwent
spirometry in the Renwick study, 26% had airflow
obstruction defined by an FEV1/FVC o65%. Ourstudy differs from the Renwick study in that we
studied patients presenting to their primary care
office, the patients’ mean age was 7 years younger
(59 years), and the communities were in rural
areas, rather than in a highly industrialized area
such as Manchester, UK. Pack years was not
described by Renwick et al. In our study, it made
a large difference. The prevalence of airflow
obstruction in the lowest quartile (o15.5 pack-
years) as 7.9% v 30.9% in those highest quartile
( X48 pack-years).
Recently Lundback et al.14 reported that 14.5% of
ex-smokers and 24.6% of current smokers had an
FEV1/FVC ratio less than 70% among 1237 commu-
nity-based subjects in Northern Sweden. Differ-
ences seen between studies in the prevalence of
airflow obstruction may potentially be explained by
differences in: age, gender, socioeconomic status,
smoking, and air pollution exposure amongst the
populations studied. Additionally, differences in
the spirometric definition of obstruction, and the
choice of reference values, can also explain
differences found between studies.
Takahashi et al. reported the first clinic-based
with two groups of people in two different settings.
One group was current and ex-smokers at least 40
years old, and the second group symptomatic
patients with no previous diagnosis of respiratory
disease. The two settings were hospital-based and
general-practice-based primary care settings. Se-
venty-six percent of the subjects were men, with a
mean age of 63 years, and the FEV1/FVC was o0.7
in 27%. Bronchodilators were not given. Study
results were not presented stratified by setting
and patient group making it hard to compare with
the results of the present study.8
Recently, Buffels et al.,9 reported that office
spirometry detected obstruction in 18% (126/703)
of patients between 35 and 75 years old with
reported cough, wheeze, breathlessness, or nasal
allergy or hay fever. Airflow obstruction was
detected in 4% (9/222) without complaints.
Obstruction was defined as an FEV1/FVC o88.5%
of the predicted value for men ando89.3% for
women. They concluded that a questionnaire did
not accurately categorize those with spirometry-
defined obstruction.
Airflow obstruction cannot be accurately
diagnosed without spirometry. We found that
obstruction was more common among those
who were older, had smoked more, had symptoms
or diagnoses of respiratory disease, and amongst
those who were taking respiratory medications.
However, of these characteristics, only physician-
diagnosis of respiratory disease and use of respira-
tory medications were at least twice as prevalent in
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Airflow obstruction in rural primary care 759the obstructed compared to the non-obstructed
group.
Airflow obstruction is under-recognized and
under-treated. Approximately half of those with
airflow obstruction were not diagnosed, and half of
those with symptoms were not treated. However,
airflow obstruction is also sometimes over-diag-
nosed. Ten percent of those with diagnosed COPD
or emphysema had both a normal FEV1 and a normal
FEV1/FVC.
Based on this primary care study, is screening
spirometry indicated in rural physicians’ offices?
Spirometry as a screening tool for lung disease
meets many of the criteria desirable in screening.15
The disease under consideration for screening
should be a major medical problem whose natural
history is understood, and accepted medical treat-
ments should be available and accessible. Asthma
and COPD are major medical problems with
predictable natural histories, and accepted medi-
cal treatments are available, such as smoking
cessation, vaccination, exercise, and medications.
Furthermore, spirometry is a relatively simple,
inexpensive, and accurate screening test that could
be made easily available in primary care practices.
Based on these criteria, spirometric screening for
obstructive lung disease is desirable, and may
improve quality of care in primary care practice.
These results support the use of screening
spirometry in primary care practice, but there are
several questions that need to be answered to
better understand the health impact. Will physi-
cians act on the spirometric findings, will patients
adhere to recommendations, and how much will
this influence health outcomes? Is spirometry best
done on-site or referred to a central community
laboratory? Who should interpret the results?
Nevertheless, the results of this study demonstrate
that spirometry, guided by simple screening criteria
easily applied in primary care, can detect a
significant number of cases of airflow obstruction,
many of which have gone undiagnosed, and many of
which are symptomatic yet untreated. Therefore,
spirometry in rural clinical practice has the
potential to improve diagnostic accuracy and
therapy for obstructive lung diseases.Acknowledgements
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